



SciGen Limited

Annual General Meeting Managing Director's Presentation

28 February 2005

**Mr Mark Compton
Chief Executive Officer and
Managing Director**



delivering human solutions...




SciGen Limited

- Biopharmaceutical company
- Expert focus on Asia Pacific Region
- Portfolio of products already marketed in 8 countries
- Rights to market proprietary and biogeneric products under licence – some global
- A number of active product registrations
- Evolving business in Europe
- Product development- therapeutic vaccine



delivering human solutions...




Products in the market

- SciTropin – human growth hormone
- Sci-B-Vac – hepatitis B vaccine
- SciLin – human insulin
- SciTojet- needle free injection device

Products in development

- SciFeron- interferon
- SciDaPT
- Therapeutic hepatitis vaccine



delivering human solutions...

FY04 & 1HFY05 Highlights

- Revenue [\$\$ million]

FY03	FY04	%
2.667	6.172	+132
1HFY04	1HFY05	%
3.132	3.9	+24

- Net result [\$\$ million]

FY03	FY04	%
4.881	4.311	-11.6
1HFY04	1HFY05	%
(1.935)	(2.19)	+13.2



delivering human solutions...

FY04 & 1HFY05 Highlights

- SciGen announced a joint development partnership with Intercell AG of Vienna, to develop the significant potential of Sci-B-Vac™ to create a therapeutic vaccine for the treatment of chronic hepatitis B infection
- Post balance date the Company announced a A\$9.3M capital raising and strategic partnership with Bioton SA of Poland
- Significantly expanded rights for global supply and European marketing for Sci-B-Vac™



delivering human solutions...

FY04 & 1HFY05 Highlights

- The final licence fee payment for sales and marketing rights of all current products was made to Savient Pharmaceuticals Inc (formerly BTG) in December 2004
- During the first half, the Company received registrations and sales commenced in India of SciTropin™ (recombinant human growth hormone) and SciLin™ (recombinant human insulin)
- BRW magazine's Top 100 Fastest Growing Companies list.



delivering human solutions...


Cashflow Statement 31 December 2004

(S\$'000)	1HFY2005	1HFY2004	%
Cash receipts from Customers	1,670	905	84.53
Net operating cashflows	(983)	(1,069)	(8.05)
Cash Balance at end of quarter	5,772	12,609	(54.22)




delivering human solutions...

Sales Revenue FY 2002 - FY2004



delivering human solutions...

Net Position FY2002 - FY2004



delivering human solutions...

Group Profit & Loss FY 2002 – FY 2004

	S\$'000	S\$'000	S\$'000	S\$'000
	FY2002	FY2003	FY2004	1HFY2005
Sales	1,204	2,667	6,172	3,470
EBITDA	(4,107)	(4,616)	(4,025)	(2,010)
NPAT	(4,244)	(4,881)	(4,311)	(2,187)



delivering human solutions...



Bioton/SciGen Investment

- Bioton SA is a high profile well established biopharmaceutical company based in Warsaw
- Current producer of insulin, antibiotics and other products
- Profitable company; due for public listing on 15 March 2005
- Synergies between companies in terms of:
 - insulin production and sale;
 - new technologies in product areas for SciGen;
 - manufacturing facility;
 - new products for SciGen;
 - access to European markets;
 - technological support and know-how;
 - strategic investor



delivering human solutions...



Bioton/SciGen Investment

Bioton transaction details

- 24% of SciGen's equity
- A\$0.07 per share
- 2 tranches
 - 1st due in the next week or so.
 - 2nd tranche subject to shareholder approval at EGM early April.
 - Total investment A\$9.3M
- Two seats on Board
- Discussions on joint initiative for manufacturing facility in Singapore



delivering human solutions....



Intercell AG

- **Development of Therapeutic Hepatitis B Vaccine**
 - Joint initiative with Intercell AG of Vienna, Austria announced on 13 Dec 2004
 - Project to combine IC 31TM Adjuvant of Intercell with SciGen's 3rd generation hepatitis B vaccine Sci-B-VacTM
 - Market for therapeutic vaccine is enormous and untouched
 - Project planning has commenced
 - Proof of Concept work commencing
 - Intercell adjuvants previously used by Aventis- Pasteur & Merck
 - Very significant value add if successful



delivering human solutions....

Berna >B— Berna Biotech AG


- Berna Biotech is a publicly listed Swiss biopharmaceutical company
- Berna has a market capitalisation of approximately \$A430M and annual sales for FY2004 of approximately \$A75M.
- In FY2004 Berna sold over \$US50M in hepatitis B and paediatric vaccines.
- Agreement announced 15 Feb '05 for Berna to be SciGen's exclusive distributor for Sci-B-Vac™ in Western Europe.
- This is the first expansion of SciGen's activity outside of the Asia Pacific Region.
- Very significant market



delivering human solutions....

Geographic Representation

- SciGen has business unit representation or partners in the following countries/regions:



delivering human solutions....

Product Portfolio

- SciGen's product portfolio comprises a range of products.

Product	Application
• Sci-B-Vac	3 rd generation hepatitis B vaccine
• SciTropin	Recombinant human growth hormone
• SciLin	Recombinant human insulin
• SciFeron	Recombinant Interferon 2b
• SciDaPt-Vac	Diphtheria, whooping cough and tetanus
• SciDaPT/HB-Vac	Diphtheria, whooping cough, tetanus and hepatitis B combination
• SciTojet 2	Needle free injection device



delivering human solutions...

Sci-B-Vac

- **Important features**
 - Sci-B-Vac™ contains purified recombinant pre-S1, S2 and S protein antigens
 - Elicits a high titre response
 - Response is fast (possibly fewer than three doses)
 - Full protection from first dose in some patients
 - Effective in immunocompromised patients
 - Highly effective in "non-responder" group (Berna study)
 - Early data suggests potential role as a therapeutic vaccine
 - Very strong interest in Region
 - Change of manufacturing site will see product return in CY06



delivering human solutions...




delivering human solutions...



SciLin


- **Important features**
 - Recombinant human insulin
 - Generic product
 - Diabetes on the increase worldwide
 - More insulin being used in treatment
 - Alternative delivery devices use more insulin
 - Worldwide insulin demand increasing

delivering human solutions...



SciLin

- Current product purchased from Bioton
- Bioton has extensive experience in insulin technology
- Collaboration between SciGen/Bioton/Shreya Biotech is likely to generate better and less expensive insulin products



delivering human solutions...

SciTojet

- SciTojet™ - Needle Free Delivery of SciTropin™ and SciLin™

Some medications can be self administered by a patient via a needle-free delivery system to which SciGen has the exclusive rights for the Asia Pacific region. The SciTojet™ releases a fine stream of drug without the use of a needle. The device aids in self-administration and leads to better compliance with therapy, especially for paediatric patients.


When pressed, the indicator button releases a fine stream of SciTropin™ without a needle

An automatic safety switch for easy control of injection

The dosage window shows how many units of SciTropin™ have been drawn into the Needle-Free Syringe

A sterile, disposable Needle-Free Syringe is reusable for 7 days

The Needle-Free Syringe provides a clear view of the full dose.



delivering human solutions...

Country Highlights

- **Australia**
 - SciTropin™ revenue well ahead of last year
 - Growth across all sectors
 - Examining other product opportunities
 - Australia provides a positive contribution as a territory.



delivering human solutions....

Country Highlights

- **Singapore**
 - SciTropin™ sales progressing well - exceeding budget YTD FY2005
 - Regulatory Affairs relocated from Sydney to Singapore to be closer to key markets
 - Close to break even in terms of contribution



delivering human solutions....

Country Highlights

- **Hong Kong**
 - New Sales Manager appointed and rejuvenating sales
 - Hong Kong-Shanghai International Liver Congress held in Hong Kong February 2004
 - Over 2,000 doctors in attendance
 - High profile given to Sci-B-Vac™
 - Sci-B-Vac™ Paediatric dose [5mcg] registered
 - SciTropin™ sales climbing



delivering human solutions....

Country Highlights

- **Philippines**
 - SciTropin™ sales revenue is improving
 - Difficult economic climate
 - Enhanced sales & marketing effort
 - Insulin registration received February 2005
 - Plans being finalised for insulin launch and sales



delivering human solutions....

Country Highlights

- **Korea**
 - SciTropin™ sales have grown significantly in the last year
 - Targeting sales calls for SciTropin™ on “growing” adult human growth hormone deficiency market
 - Pursuing other product registrations and increasing coverage with regional distributors



delivering human solutions...

Country Highlights

- **Vietnam**
 - Sci-B-Vac™ and SciLin™ being sold
 - Exposure of SciGen gaining momentum
 - Insulin sales beginning to improve
 - Human growth hormone registered and launch planned for March '05



delivering human solutions...


India Country Highlights

- Insulin registered and sales commenced by Shreya in December 2004
- Ranbaxy due to launch sales before end of FY'05
- Too early to give guidance on sales levels
- SciTropin™ and SciTojet™ both registered and launched
- Sci-B-Vac™ registration still underway



delivering human solutions....

Thanks to all the wonderful
SciGen Staff, Partners & Customers!



delivering human solutions....



SciGen Limited

Annual General Meeting Managing Director's Presentation

28 February 2005

**Mr Mark Compton
Chief Executive Officer and
Managing Director**



delivering human solutions...